NASDAQ:INMB

Inmune Stock News

Healthcare > Biotechnology

Buy INMB

*Your capital is at risk

$2.09

+0.180 (+9.42%)

At Close: Aug 07, 2026

INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th

07:00am, Monday, 05'th May 2025

Boca Raton, Florida, May 05, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting microglial activation and n

INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness

08:00am, Monday, 14'th Apr 2025

Stevenage, UK, and Boca Raton, Florida, US, April 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) a clinical-stage biotechnology company targeting inflammation and immunology through the

INmune Bio, Inc. (INMB) Q4 2024 Earnings Call Transcript

08:15pm, Thursday, 27'th Mar 2025

INmune Bio, Inc. (NASDAQ:INMB ) Q4 2024 Results Conference Call March 27, 2025 4:30 PM ET Company Participants David Moss - CFO Raymond Tesi - CEO & Co-Founder Mark Lowdell - Chief Scientific Officer

INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update

04:05pm, Thursday, 27'th Mar 2025

BOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that ha

Undercovered Dozen: INmune Bio, Primerica, First Quantum, Pinnacle West +

01:15pm, Friday, 21'st Mar 2025

The 'Undercovered' Dozen series highlights 12 lesser-covered stocks, offering fresh ideas and fostering discussion among investors. Mitsui & Co. is given a 'buy' recommendation, driven by Warren Buffe

INmune Bio: CORDstrom Is A Game-Changer, As Investors Await Alzheimer's Results

04:31pm, Tuesday, 18'th Mar 2025

INmune Bio's CORDstrom for RDEB shows promising results, supported by FDA designations, and could lead to a 9.8x stock revaluation. XPro for Alzheimer's has significant potential, with a $24.76 billio

INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer

07:00am, Wednesday, 12'th Feb 2025

BOCA RATON, Fla, Feb. 12, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK

INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

07:00am, Monday, 10'th Feb 2025

Boca Raton, Florida, Feb. 10, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”) , a clinical-stage inflammation and immunology company focused on developing treatments th

INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025

08:52am, Thursday, 02'nd Jan 2025

INmune Bio's XPro targets neuroinflammation, showing promising biomarker results in Alzheimer's, with a potential to outperform current treatments and attract big pharma interest. The Phase 2 trial fo

INmune Bio: XPro Cognitive Readout In Sight, But Mind The Financial Dangers

03:20pm, Monday, 30'th Dec 2024

INmune Bio, Inc.'s decline in 2024 is attributed to broader biotech sector issues, lack of significant clinical data, and inherent risks in Alzheimer's research. XPro, INMB's lead candidate, shows pot

OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower

09:00am, Wednesday, 04'th Dec 2024

Vivo Empowers Clinical Development Teams to Accelerate Decision-making and Analyses in Clinical Trials for Improved Outcomes HOUSTON and BOCA RATON, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- OmniScience

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by